INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
INmune Bio advanced its CORDStrom platform patent application into the U.S. national phase after receiving a favorable Written Opinion during the international phase. The patent application seeks protection for composition-of-matter and methods of treatment for Ebstrocel and next-generation modalities, with exclusivity potentially extending to 2045.
Key figures
- Patent protection expires
- 2045
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.